| scholarly article | Q13442814 |
| P2093 | author name string | H Lennernäs | |
| B Jansson | |||
| L Knutson | |||
| T W Knutson | |||
| R Sandström | |||
| P2860 | cites work | Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects | Q30966752 |
| Comparison between permeability coefficients in rat and human jejunum | Q34063545 | ||
| The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors | Q34065800 | ||
| Expression of a multidrug-resistance gene in human tumors and tissues | Q34586576 | ||
| Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man | Q35580014 | ||
| Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine | Q36031211 | ||
| Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression | Q37367800 | ||
| Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. | Q40449494 | ||
| Kinetics of the multidrug transporter (P-glycoprotein) and its reversal | Q41441350 | ||
| Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells | Q41492388 | ||
| Pharmacokinetics of felodipine in patients with liver disease | Q42646696 | ||
| Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine* | Q44872539 | ||
| Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism | Q51030961 | ||
| Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism | Q51530623 | ||
| First-pass metabolism of midazolam by the human intestine. | Q51568384 | ||
| Regional rectal perfusion: a new in vivo approach to study rectal drug absorption in man. | Q52349665 | ||
| Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein | Q52534774 | ||
| Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man | Q67591105 | ||
| A new technique for segmental jejunal perfusion in man | Q69768583 | ||
| Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans | Q70123371 | ||
| Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships | Q71350714 | ||
| Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin | Q71650801 | ||
| Enantioselective distribution of verapamil and norverapamil into human and rat erythrocytes: the role of plasma protein binding | Q71730856 | ||
| Jejunal permeability and hepatic extraction of fluvastatin in humans | Q71828066 | ||
| Simultaneous analysis of verapamil and norverapamil enantiomers in human plasma by high-performance liquid chromatography | Q72032420 | ||
| Enantiometric separation of verapamil and norverapamil using Chiral-AGP as the stationary phase | Q73509050 | ||
| Tacrolimus oral bioavailability doubles with coadministration of ketoconazole* | Q73562532 | ||
| Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine* | Q73794585 | ||
| Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical | Q74144243 | ||
| Jejunal absorption and metabolism of R/S-verapamil in humans | Q74731555 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 180-189 | |
| P577 | publication date | 1999-08-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans | |
| P478 | volume | 48 |
| Q46920376 | An examination of the effect of intestinal first pass extraction on intestinal lymphatic transport of saquinavir in the rat. |
| Q46250438 | Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers |
| Q46438864 | Blood concentrations of everolimus are markedly increased by ketoconazole |
| Q35553211 | Clinical Pharmacokinetics of Atorvastatin |
| Q33858325 | Effects of the antifungal agents on oxidative drug metabolism: clinical relevance |
| Q44428854 | Enantioselective transport and CYP3A4-mediated metabolism of R/S-verapamil in Caco-2 cell monolayers |
| Q42597779 | Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors |
| Q38107970 | Experimental models for predicting drug absorption and metabolism |
| Q24648374 | Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy |
| Q37920916 | In vitroandin vivosmall intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences |
| Q43788758 | Increased susceptibility of a triclabendazole (TCBZ)-resistant isolate of Fasciola hepatica to TCBZ following co-incubation in vitro with the P-glycoprotein inhibitor, R(+)-verapamil |
| Q45850124 | Influence of Pluronic 85 and ketoconazole on disposition and efficacy of ivermectin in sheep infected with a multiple resistant Haemonchus contortus isolate |
| Q35153169 | Intestinal drug absorption and bioavailability: beyond involvement of single transport function |
| Q36985043 | Intestinal permeability and its relevance for absorption and elimination |
| Q44785715 | Metabolism of propafenone and verapamil by cryopreserved human, rat, mouse and dog hepatocytes: comparison with metabolism in vivo. |
| Q34093099 | P-glycoprotein and bioavailability-implication of polymorphism |
| Q36885663 | Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel |
| Q43672189 | Profound effect of plasma protein binding on the polarized transport of furosemide and verapamil in the Caco-2 model |
| Q31046543 | The effect of amiloride on the in vivo effective permeability of amoxicillin in human jejunum: experience from a regional perfusion technique |
| Q35846680 | The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique |
| Q45162718 | The effect of quercetin on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rabbits |
| Q43862251 | The impact of P-glycoprotein efflux on enterocyte residence time and enterocyte-based metabolism of verapamil. |
| Q36535786 | Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. |
Search more.